Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia
- PMID: 2280177
Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia
Abstract
Familial defective apolipoprotein B-100 is a genetic disorder of apolipoprotein B-100 that causes moderate to severe hypercholesterolemia. A single amino acid mutation in apolipoprotein B diminishes the ability of low density lipoproteins to bind to the low density lipoprotein receptor. Low density lipoproteins accumulate in the plasma because their efficient receptor-mediated catabolism is disrupted. This mutation has been identified in the United States, Canada, and Europe and is estimated to occur at a frequency of approximately 1/500 in these populations. Thus, it appears that this newly described disorder may be a significant genetic cause of hypercholesterolemia in Western societies.
Similar articles
-
Familial defective apolipoprotein B-100 is clinically indistinguishable from familial hypercholesterolemia.Arch Intern Med. 1993 Oct 25;153(20):2349-56. Arch Intern Med. 1993. PMID: 8215738
-
Familial defective apolipoprotein B-100: a single mutation that causes hypercholesterolemia and premature coronary artery disease.Atherosclerosis. 1992 Oct;96(2-3):91-107. doi: 10.1016/0021-9150(92)90056-m. Atherosclerosis. 1992. PMID: 1466657 Review.
-
Clinical signs of familial hypercholesterolemia in patients with familial defective apolipoprotein B-100 and normal low density lipoprotein receptor function.Arterioscler Thromb. 1991 May-Jun;11(3):691-703. doi: 10.1161/01.atv.11.3.691. Arterioscler Thromb. 1991. PMID: 1674216
-
Familial defective apolipoprotein B-100.Dan Med Bull. 1998 Sep;45(4):370-82. Dan Med Bull. 1998. PMID: 9777289 Review.
-
Familial defective apolipoprotein B-100: a common cause of primary hypercholesterolemia.Clin Investig. 1992 Jan;70(1):77-84. doi: 10.1007/BF00422946. Clin Investig. 1992. PMID: 1600334 Review.
Cited by
-
Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation.J Biol Chem. 2013 Mar 22;288(12):8279-8288. doi: 10.1074/jbc.M112.421370. Epub 2013 Feb 11. J Biol Chem. 2013. PMID: 23400816 Free PMC article.
-
The genetics of familial hypercholesterolemia and emerging therapies.Appl Clin Genet. 2015 Jan 28;8:27-36. doi: 10.2147/TACG.S44315. eCollection 2015. Appl Clin Genet. 2015. PMID: 25670911 Free PMC article. Review.
-
The promise of proprotein convertase subtilisin/kexin 9 inhibitors for the treatment of familial hypercholesterolemia.Curr Atheroscler Rep. 2015 May;17(5):508. doi: 10.1007/s11883-015-0508-7. Curr Atheroscler Rep. 2015. PMID: 25782778 Review.
-
ApoB siRNA-induced liver steatosis is resistant to clearance by the loss of fatty acid transport protein 5 (Fatp5).Lipids. 2011 Nov;46(11):991-1003. doi: 10.1007/s11745-011-3596-3. Epub 2011 Aug 9. Lipids. 2011. PMID: 21826528 Free PMC article.
-
Decreased bone mineral density in subjects carrying familial defective apolipoprotein B-100.J Clin Endocrinol Metab. 2013 Dec;98(12):E1999-2005. doi: 10.1210/jc.2013-2471. Epub 2013 Oct 8. J Clin Endocrinol Metab. 2013. PMID: 24106285 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources